10-K/A: Xencor Restates 2023 Financials Due to Accounting Errors, Identifies Material Weaknesses

Xencor restated its 2023 financial statements due to errors in royalty accounting and tax treatment, leading to the identification of material weaknesses in internal controls.

Summary

• Xencor has restated its audited consolidated financial statements for the fiscal year ended December 31, 2023, due to errors related to the accounting treatment of a royalty transaction with OMERS Life Sciences, the unrecorded tax benefit related to research and development expenses, and an understatement of state tax obligations.
• The royalty transaction was incorrectly accounted for as deferred income and should have been accounted for as debt.
• The company also understated research and experimental expenses that should have been capitalized for tax purposes and understated its state income tax expense.
• The impact on the consolidated balance sheet as of December 31, 2023, included an understatement of accounts receivable by $12.4 million, an overstatement of deferred income by $156.9 million, an understatement of debt by $168.5 million, and an understatement of shareholders' equity by $0.8 million.
• The impact on the consolidated statement of loss for the year ended December 31, 2023, included an understatement of revenue by $6.3 million and an understatement of interest expense by $5.5 million.
• The impact on the consolidated statement of cash flows for the year ended December 31, 2023, included an overstatement of cash flow provided by operating activities by $163.0 million and an understatement of cash flow provided by financing activities by the same amount.
• The company also identified an uncertain tax position of $6.2 million owed for the fiscal year ended December 31, 2023, and understated its state income tax expense by approximately $2.1 million, net of federal benefit.
• As a result of the restatement, management has re-evaluated the effectiveness of the company's internal control over financial reporting as of December 31, 2023, and concluded that additional material weaknesses exist.
• Management plans to implement a more rigorous analysis of non-routine transactions, improve the process to identify and select qualified third-party advisors, enhance the review of capabilities and work performed by third-party advisors, and review income tax legislative changes quarterly with a tax expert.

Sentiment

Score: 4

Explanation: The document highlights significant accounting errors and material weaknesses, which negatively impact investor confidence. While the company is taking steps to remediate these issues, the overall sentiment is cautious due to the potential risks and uncertainties associated with the restatement.

Positives

• The company is taking steps to remediate the identified material weaknesses in its internal control over financial reporting.
• Management is committed to improving the accuracy and reliability of its financial reporting.

Negatives

• The restatement indicates errors in the company's previous financial reporting.
• The identification of material weaknesses in internal control over financial reporting raises concerns about the company's ability to accurately report its financial condition and results of operations.
• The restatement may negatively impact investor confidence in the company.

Risks

• Failure to remediate the identified material weaknesses could lead to future misstatements in the company's financial statements.
• The restatement and identification of material weaknesses could result in increased scrutiny from regulators and investors.
• The company's stock price could be negatively impacted by the restatement and the identification of material weaknesses.

Future Outlook

Xencor expects its existing cash, cash equivalents and marketable securities, together with interest thereon and expected milestones and royalty payments will be sufficient to fund its operations into 2027.

Management Comments

• Management plans to implement a more rigorous analysis of non-routine transactions.
• Management will improve the process to identify and select qualified third-party advisors on highly technical and complex accounting transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors specifically related to the review of accounting guidance for complex non-routine transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors related to the review of tax advice.
• Management will review income tax legislative changes and their impact to our financial statements with our tax expert on a quarterly basis.

Industry Context

The biopharmaceutical industry is subject to intense competition and rapidly advancing technologies. Xencor competes with other companies for promising targets for antibody-based therapeutics, new technology for optimizing antibodies and cytokines, and in recruiting highly qualified personnel.

Comparison to Industry Standards

• Many competitors and potential competitors have substantially greater scientific, research, and product development capabilities as well as greater financial, marketing and sales, and human resources than Xencor does.
• Many specialized biotechnology firms have formed collaborations with large, established companies to support the research, development, and commercialization of products that may be competitive with Xencor's.
• Competition in the field of cancer drug development is intense, with hundreds of compounds in clinical trials.
• Many large pharmaceutical companies and other smaller biotechnology companies are developing competing bispecific antibody platforms, including Amgen Inc.; Genmab A/S; Macrogenics, Inc.; Merus N.V.; Regeneron Pharmaceuticals, Inc.; and Roche Holding AG.
• Other companies conducting clinical trials to evaluate CD3 or CD28 bispecific antibodies directed to antigens expressed on solid tumors include Amgen Inc.; Astellas Pharma Inc.; BioAtla, Inc.; CytomX Therapeutics, Inc.; Genmab A/S; Immunocore Holdings plc; Janux Therapeutics, Inc.; Johnson & Johnson; Regeneron Pharmaceuticals, Inc.; Roche Holding AG; and Takeda Pharmaceutical Co. Ltd.

Corporate Governance

Stakeholder Impact

• Shareholders may experience a decrease in the value of their investment due to the restatement and the identification of material weaknesses.
• Employees may be affected by the company's cost-cutting measures, including reductions in the workforce.
• Customers and partners may be impacted by any delays or disruptions in the company's research and development programs.

Next Steps

• Management plans to implement a more rigorous analysis of non-routine transactions.
• Management will improve the process to identify and select qualified third-party advisors on highly technical and complex accounting transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors specifically related to the review of accounting guidance for complex non-routine transactions.
• Management will enhance the review of capabilities and work performed by third-party advisors related to the review of tax advice.
• Management will review income tax legislative changes and their impact to our financial statements with our tax expert on a quarterly basis.

Key Dates

Keywords

restatement, financial statements, material weaknesses, internal control, royalty transaction, tax obligations, Xencor, OMERS, accounting errors